Use case
Expanded-access leads or clinical teams at drugmakers assess whether a seriously ill patient can enter compassionate use, working through program eligibility and drug documents to locate available programs and decide the next application step.
Today this mostly relies on manually searching drugmaker program pages and industry directories, emailing contacts, or personal networks.
Expanded-access program information is scattered across drugmakers with inconsistent fields, so manual page-by-page lookup is slow and can miss available programs; a wrong judgment delays access for seriously ill patients.
xOcto's call
Demand is evidenced
Trend: regulated industry data is being exposed to general AI assistants through interfaces like MCP, and data holders are competing to be the source assistants cite. Entry: start from high-compliance, low-transparency information steps such as compassionate use and trial recruitment, selling traceable data licensing and updates rather than the assistant itself; pricing is not disclosed.
Reason to use it
Why users would choose it
Inference: compared with page-by-page manual search, the MCP server lets AI assistants pull structured program data directly in conversation, cutting the step of locating and comparing programs; drugmakers or clinical teams screening multiple programs quickly would choose it in that situation, but no user feedback or adoption data is public.
Where the easy answer breaks down
The tension worth following
An English validation note will follow from the public evidence.
If this is your job
Worth trying. Inference: compared with page-by-page manual search, the MCP server lets AI assistants pull structured program data directly in conversation, cutting the step of locating and comparing programs; drugmakers or clinical teams screening multiple programs quickly would choose it in that situation, but no user feedback or adoption data is public.
Entry and what to borrow
Trend: regulated industry data is being exposed to general AI assistants through interfaces like MCP, and data holders are competing to be the source assistants cite. Entry: start from high-compliance, low-transparency information steps such as compassionate use and trial recruitment, selling traceable data licensing and updates rather than the assistant itself; pricing is not disclosed.